The shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been pegged with a rating of Neutral by Credit Suisse in its latest research note that was published on July 10th, 2019. Credit Suisse wasn’t the only research firm that published a report of Ironwood Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. Morgan Stanley advised investors in its research note published on March 27th, 2019, to Equal-Weight the IRWD stock. The stock had earned Neutral rating from H.C. Wainwright when it published its report on February 25th, 2019. That day the H.C. Wainwright set price target on the stock to $14. The stock was given Neutral rating by JP Morgan in its report released on January 24th, 2019. JP Morgan was of a view that IRWD is Underweight in its latest report on November 7th, 2018. Credit Suisse thinks that IRWD is worth Neutral rating. This was contained in the firm’s report on November 7th, 2018.
The consensus currently stands at a Hold while its average price target is $14.89. The price of the stock the last time has raised by 22.90% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 48.98.
The shares of the company added by 0.65% during the trading session on Wednesday, reaching a low of $9.08 while ending the day at $9.33. During the trading session, a total of 2.54 million shares were traded which represents a -55.57% decline from the average session volume which is 1.63M shares. IRWD had ended its last session trading at 9.27. Ironwood Pharmaceuticals, Inc. currently has a market cap of $1.46B while its P/E earnings growth sits at 3.98, with a beta of 1.77. IRWD 52-week low price stands at $7.59 while its 52-week high price is $16.26.
Investment analysts at SunTrust published a research note on September 5th, 2019 where it informed investors and clients that Match Group, Inc. (NASDAQ:MTCH) is now rated as Buy. Their price target on the stock stands at $106. Morgan Stanley also rated MTCH as Upgrade on March 27th, 2019, with its price target of $27 suggesting that MTCH could surge by 1.96% from its current share price. Even though the stock has been trading at $83.98/share, analysts expect it to surge higher by 1.98% to reach $87.35/share. It started the day trading at $86.06 and traded between $84.10 and $85.64 throughout the trading session.
A look at its technical shows that MTCH’s 50-day SMA is 77.73 while its 200-day SMA stands at 60.87. The stock has a high of $95.32 for the year while the low is $31.69. The company’s P/E ratio currently sits at 50.64, while the P/B ratio is 114.19. At the moment, only of Match Group, Inc. shares were sold short. The company’s average trading volume currently stands at 1.99M shares, which means that the short-interest ratio is just 12.38 days. Over the past seven days, the company moved, with its shift of 0.95%. Looking further, the stock has raised 20.04% over the past 90 days while it gained 56.56% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Sands Capital Management LLC sold more MTCH shares, decreasing its portfolio by -2.59% during the last quarter. This move now sees Sands Capital Management LLC selling -260,391 shares in the last quarter, thus it now holds 9,788,897 shares of MTCH, with a total valuation of $737,006,055. The Vanguard Group Inc meanwhile bought more MTCH shares in the recently filed quarter, changing its stake to $473,915,314 worth of shares. JPMorgan Investment Management I followed the path by increasing its MTCH portfolio by +7.57% in the quarter. This means that JPMorgan Investment Management I bought 348,503 shares in the last quarter and now controls 4,954,749 shares of the MTCH stock, with the valuation hitting $373,043,052.
Similarly, D E Shaw Co LP decreased its Match Group, Inc. shares by -0.84% during the recently filed quarter. After selling -17,827 shares in the last quarter, the firm now controls 2,092,963 shares of Match Group, Inc. which are valued at $157,579,184. In the same vein, BlackRock Fund Advisors increased its Match Group, Inc. shares by during the most recent reported quarter. The firm bought 27,580 shares during the quarter which increased its stakes to 2,067,123 shares and is now valued at $155,633,691. Following these latest developments, around 23.50% of Match Group, Inc. stocks are owned by institutional investors and hedge funds.